Cargando…

A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy

BACKGROUND: There is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez-Quiceno, Laura, Dammer, Eric B., Johnson, Ashlyn Grace, Webster, James A., Shah, Rhythm, Duong, Duc, Yin, Luming, Seyfried, Nicholas T., Alvarez, Victor E., Stein, Thor D., McKee, Ann C., Hales, Chadwick M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235576/
https://www.ncbi.nlm.nih.gov/pubmed/34172091
http://dx.doi.org/10.1186/s13024-021-00462-3
_version_ 1783714351755034624
author Gutierrez-Quiceno, Laura
Dammer, Eric B.
Johnson, Ashlyn Grace
Webster, James A.
Shah, Rhythm
Duong, Duc
Yin, Luming
Seyfried, Nicholas T.
Alvarez, Victor E.
Stein, Thor D.
McKee, Ann C.
Hales, Chadwick M.
author_facet Gutierrez-Quiceno, Laura
Dammer, Eric B.
Johnson, Ashlyn Grace
Webster, James A.
Shah, Rhythm
Duong, Duc
Yin, Luming
Seyfried, Nicholas T.
Alvarez, Victor E.
Stein, Thor D.
McKee, Ann C.
Hales, Chadwick M.
author_sort Gutierrez-Quiceno, Laura
collection PubMed
description BACKGROUND: There is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. Here, we hypothesized that identifying the human brain proteome from serial CTE stages (CTE I-IV) would provide critical new insights into CTE pathogenesis. Brain samples from frontotemporal lobar degeneration due to microtubule associated protein tau (FTLD-MAPT) mutations were also included as a distinct tauopathy phenotype for comparison. METHODS: Isobaric tandem mass tagged labeling and mass spectrometry (TMT-MS) followed by integrated differential and co-expression analysis (i.e., weighted gene co-expression network analysis (WGCNA)) was used to define modules of highly correlated proteins associated with clinical and pathological phenotypes in control (n = 23), CTE (n = 43), and FTLD-MAPT (n = 12) post-mortem cortical tissues. We also compared these findings to network analysis of AD brain. RESULTS: We identified over 6000 unique proteins across all four CTE stages which sorted into 28 WGCNA modules. Consistent with Alzheimer’s disease, specific modules demonstrated reduced neuronal protein levels, suggesting a neurodegeneration phenotype, while other modules were increased, including proteins associated with inflammation and glial cell proliferation. Notably, unique CTE-specific modules demonstrated prominent enrichment of immunoglobulins, including IGHM and IGLL5, and extracellular matrix (ECM) proteins as well as progressive protein changes with increasing CTE pathologic stage. Finally, aggregate cell subtype (i.e., neurons, microglia, astrocytes) protein abundance levels in CTE cases were similar in expression to AD, but at intermediate levels between controls and the more exaggerated phenotype of FTLD-MAPT, especially in astrocytes. CONCLUSIONS: Overall, we identified thousands of protein changes in CTE postmortem brain and demonstrated that CTE has a pattern of neurodegeneration in neuronal-synaptic and inflammation modules similar to AD. We also identified unique CTE progressive changes, including the enrichment of immunoglobulins and ECM proteins even in early CTE stages. Early and sustained changes in astrocyte modules were also observed. Overall, the prominent overlap with FTLD-MAPT cases confirmed that CTE is on the tauopathy continuum and identified CTE stage specific molecular phenotypes that provide novel insights into disease pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00462-3.
format Online
Article
Text
id pubmed-8235576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82355762021-06-28 A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy Gutierrez-Quiceno, Laura Dammer, Eric B. Johnson, Ashlyn Grace Webster, James A. Shah, Rhythm Duong, Duc Yin, Luming Seyfried, Nicholas T. Alvarez, Victor E. Stein, Thor D. McKee, Ann C. Hales, Chadwick M. Mol Neurodegener Research Article BACKGROUND: There is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. Here, we hypothesized that identifying the human brain proteome from serial CTE stages (CTE I-IV) would provide critical new insights into CTE pathogenesis. Brain samples from frontotemporal lobar degeneration due to microtubule associated protein tau (FTLD-MAPT) mutations were also included as a distinct tauopathy phenotype for comparison. METHODS: Isobaric tandem mass tagged labeling and mass spectrometry (TMT-MS) followed by integrated differential and co-expression analysis (i.e., weighted gene co-expression network analysis (WGCNA)) was used to define modules of highly correlated proteins associated with clinical and pathological phenotypes in control (n = 23), CTE (n = 43), and FTLD-MAPT (n = 12) post-mortem cortical tissues. We also compared these findings to network analysis of AD brain. RESULTS: We identified over 6000 unique proteins across all four CTE stages which sorted into 28 WGCNA modules. Consistent with Alzheimer’s disease, specific modules demonstrated reduced neuronal protein levels, suggesting a neurodegeneration phenotype, while other modules were increased, including proteins associated with inflammation and glial cell proliferation. Notably, unique CTE-specific modules demonstrated prominent enrichment of immunoglobulins, including IGHM and IGLL5, and extracellular matrix (ECM) proteins as well as progressive protein changes with increasing CTE pathologic stage. Finally, aggregate cell subtype (i.e., neurons, microglia, astrocytes) protein abundance levels in CTE cases were similar in expression to AD, but at intermediate levels between controls and the more exaggerated phenotype of FTLD-MAPT, especially in astrocytes. CONCLUSIONS: Overall, we identified thousands of protein changes in CTE postmortem brain and demonstrated that CTE has a pattern of neurodegeneration in neuronal-synaptic and inflammation modules similar to AD. We also identified unique CTE progressive changes, including the enrichment of immunoglobulins and ECM proteins even in early CTE stages. Early and sustained changes in astrocyte modules were also observed. Overall, the prominent overlap with FTLD-MAPT cases confirmed that CTE is on the tauopathy continuum and identified CTE stage specific molecular phenotypes that provide novel insights into disease pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00462-3. BioMed Central 2021-06-25 /pmc/articles/PMC8235576/ /pubmed/34172091 http://dx.doi.org/10.1186/s13024-021-00462-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Gutierrez-Quiceno, Laura
Dammer, Eric B.
Johnson, Ashlyn Grace
Webster, James A.
Shah, Rhythm
Duong, Duc
Yin, Luming
Seyfried, Nicholas T.
Alvarez, Victor E.
Stein, Thor D.
McKee, Ann C.
Hales, Chadwick M.
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
title A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
title_full A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
title_fullStr A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
title_full_unstemmed A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
title_short A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
title_sort proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235576/
https://www.ncbi.nlm.nih.gov/pubmed/34172091
http://dx.doi.org/10.1186/s13024-021-00462-3
work_keys_str_mv AT gutierrezquicenolaura aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT dammerericb aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT johnsonashlyngrace aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT websterjamesa aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT shahrhythm aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT duongduc aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT yinluming aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT seyfriednicholast aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT alvarezvictore aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT steinthord aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT mckeeannc aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT haleschadwickm aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT gutierrezquicenolaura proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT dammerericb proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT johnsonashlyngrace proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT websterjamesa proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT shahrhythm proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT duongduc proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT yinluming proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT seyfriednicholast proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT alvarezvictore proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT steinthord proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT mckeeannc proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy
AT haleschadwickm proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy